Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03649321 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03649321 is a Phase 1 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 9 participants.
The verdict
NCT03649321, a Phase 1 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Determine the overall response rate (ORR) of bemcentinib plus chemotherapy (nab-paclitaxel/gemcitabine) in patients with metastatic pancreatic adenocarcinoma.
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Bemcentinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-01-03 |
| Est. Completion | 2022-06-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03649321
The ClinicalTrials.gov registry entry for NCT03649321 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT03649321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03649321 about?
NCT03649321 is a clinical study titled "Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer". Determine the overall response rate (ORR) of bemcentinib plus chemotherapy (nab-paclitaxel/gemcitabine) in patients with metastatic pancreatic adenocarcinoma.
What is the current status of trial NCT03649321?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-01-03. Estimated completion is 2022-06-27.
What interventions are being tested in trial NCT03649321?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Bemcentinib (DRUG).
Who is sponsoring clinical trial NCT03649321?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.